Abstract
The investigators conducted a multicenter open-label longitudinal study with randomized placebo-controlled double-blind maintenance phase to evaluate the effect of risperidone augmentation of citalopram for relapse prevention in older patients with antidepressant-resistant depression.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Reference
Alexopoulos GS, Canuso CM, Gharabawi GM, Bossie CA, Greenspan A, Turkoz I, Reynolds C 3rd. Placebo-controlled study of relapse prevention with risperidone augmentation in older patients with resistant depression. Am J Geriatr Psychiatry. 2008;16(1):21–30.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Eichenberger, A., de Abreu, I.D., Vela, D., Tusken, M., Camp, M.“. (2022). Placebo-Controlled Study of Relapse Prevention with Risperidone Augmentation in Older Patients with Resistant Depression. In: Tampi, R.R., Tampi, D.J., Young, J.J., Balasubramaniam, M., Joshi, P. (eds) Essential Reviews in Geriatric Psychiatry. Springer, Cham. https://doi.org/10.1007/978-3-030-94960-0_34
Download citation
DOI: https://doi.org/10.1007/978-3-030-94960-0_34
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-94959-4
Online ISBN: 978-3-030-94960-0
eBook Packages: MedicineMedicine (R0)